Neuropsychiatric aspects of Parkinson's disease

Psychosomatics

Volumn 41, Issue 1, 2000, Pages 15-23

  Marsh, Laura ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE DERIVATIVE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORTRIPTYLINE; SELEGILINE; TRAZODONE;

AFFECTIVE NEUROSIS; ANXIETY; APATHY; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PHYSICAL DISABILITY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOTHERAPY;

EID: 0033959888     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0033-3182(00)71169-8     Document Type: Article

References (103)

1. Parkinson J: An Essay on the Shaking Palsy. London, UK, Sherwood, Neely, and Jones, 1817
2. Cummings JL: Understanding Parkinson disease. JAMA 1999; 281:376-378
3. Tanner CM, Hubble JP, Chan P: Epidemiology and genetics of Parkinson's disease, in Movement Disorders: Neurologic Principles and Practice. Edited by Watts RK, Koller WC. New York, McGraw-Hill, 1997, pp 137-152
4. Hughes AJ, Daniel SE, Kilford L, et al: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184
5. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56:33-39
6. Gonera EG, van't Hof M, Berger JC, et al: Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 1997; 12:871-876
7. Hoehn MM, Yahr MD: Parkinsonism: onset, progression, and mortality. Neurology 1967; 17:427-442
8. Martin WE, Loewenson RB, Resch JA, et al: Parkinson's disease: clinical analysis of 100 patients. Neurology 1973; 23:783-790
9. Shulman LM, Singer C, Bean JA, et al: Internal tremor in patients with Parkinson's disease. Mov Disord 1996; 11:3-7
10. Cooper JA, Sagar HJ, Jordan N, et al: Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991; 114:2095-2122
11. Cooper JA, Sagar HJ, Doherty SM, et al: Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease: a follow-up study of untreated patients. Brain 1992; 115:1701-1725
12. Levin BE, Katzen HL: Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease. Adv Neurol 1995; 65:85-95
13. Dubois B, Pillon B: Cognitive deficits in Parkinson's disease. J Neurol 1997; 244:2-8
14. Gotham AM, Brown RG, Marsden CD: "Frontal" cognitive function in patients with Parkinson's disease "on" and "off" levodopa. Brain 1988; 111:299-321
15. Mayeux R, Stern Y, Rosen J, et al: Depression, intellectual impairment, and Parkinson disease. Neurology 1981; 31:645-650
16. Sano M, Stern Y, Williams J, et al: Coexisting dementia and depression in Parkinson's disease. Arch Neurol 1989; 46:1284-1286
17. Mohr E, Litvan I, Williams J, et al: Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function. Can J Neurol Sci 1990; 17:292-297
18. Mohr E, Mendis T, Grimes JD: Late cognitive changes in Parkinson's disease with an emphasis on dementia. Adv Neurol 1995; 65:97-113
19. Goetz CG, Stebbins GT: Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43:2227-2229
20. Jankovic J: New and emerging therapies for Parkinson's disease. Arch Neurol 1999; 56:785-790
21. Young BK, Camicioli R, Ganzini L: Neuropsychiatric adverse effects of antiparkinsonian drugs: characteristics, evaluation and treatment. Drugs Aging 1997; 10:367-383
22. Olanow CW, Koller WC: An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology 1998; 50(suppl 3):S1-S57
23. Koller WC, Rueda MG: Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology 1998; 50(suppl 6):S11-S14
24. Cantello R, Gilli M, Riccio A, et al: Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study. J Neurol Neurosurg Psychiatry 1986; 49:1182-1190
25. Marsden CD, Parkes JD: Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977; 1:345-349
26. Quinn NP: Classification of fluctuations in patients with Parkinson's disease. Neurology 1998; 51 (suppl 2):S25-S29
27. Brown RG, Marsden CD, Quinn N, et al: Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984; 47:454-465
28. Nissenbaum H, Quinn NP, Brown RG, et al: Mood swings associated with the "on-off" phenomenon in Parkinson's disease. Psychol Med 1987; 17:899-904
29. Maricle RA, Nutt JG, Carter JH: Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings. Mov Disord 1995; 10:329-332
30. Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, et al: "Panic attacks" in Parkinson's disease: a long-term complication of levodopa therapy. Acta Neurol Scand 1993; 87:14-18
31. Marsh L, Cahn DA, Spears S, et al. Anxiety in Parkinson's disease: relationship to cognitive function (abstract). J Neuropsychiatry Clin Neurosci 1998; 9:653
32. Riordan HJ, Flashman LA, Roberts DW: Neurocognitive and psychosocial correlates of ventroposterolateral pallidotomy surgery in Parkinson's disease. Neurosurg Focus 1997; 2:1-9
33. Marsh L, Solvasson B, Cahn DA, et al: Psychiatric outcome after pallidotomy for Parkinson's disease (abstract). Biol Psychiatry 1997; 41(suppl):107S
34. Masterman D, DeSalles A, Baloh RW, et al: Motor, cognitive, and behavioral performance following unilateral ventroposterior pallidotomy for Parkinson disease. Arch Neurol 1998; 55:1201-1208
35. Olanow CW, Kordower JH, Freeman TB: Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19:102-109
36. Mindham RH: Psychiatric symptoms in Parkinsonism. J Neurol Neurosurg Psychiatry 1970; 33:188-191
37. Alexander GE, DeLong MR, Strick PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9:357-381
38. Wichmann T, DeLong MR: Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996; 6:751-758
39. Paulus W, Jellinger K: The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991; 50:743-755
40. Starkstein SE, Mayberg HS: Depression in Parkinson's disease, in Depression in Neurologic Disease, edited by Starkstein SE, Robinson RG. Baltimore, MD, Johns Hopkins University Press, 1993, pp 97-116
41. Mayeux R: The mental state in Parkinson's disease, in Handbook of Parkinson's Disease, 2nd Edition. Edited by Koller WC. New York, Marcel Dekker, 1992, pp 159-184
42. Cummings JL: Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149:443-454
43. Schiffer RB, Kurlan R, Rubin A, et al: Evidence for atypical depression in Parkinson's disease. Am J Psychiatry 1988; 145:1020-1022
44. Santamaria J, Tolosa E, Valles A: Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36:1130-1133
45. Fukunishi I, Hosokawa K, Ozaki S: Depression antedating the onset of Parkinson's disease. Jpn J Psychiatry Neurol 1991; 45:7-11
46. Gotham AM, Brown RG, Marsden CD: Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49:381-389
47. Huber S, Paulson GW, Shuttleworth EC: Depression in Parkinson's disease. Neuropsychiatry Neuropsychol Behav Neurol 1988; 1:47-51
48. Starkstein SE, Preziosi TJ, Bolduc PL, et al: Depression in Parkinson's disease. J Nerv Ment Dis 1990; 178:27-31
49. Horn S: Some psychological factors in Parkinsonism. J Neurol Neurosurg Psychiatry 1974; 37:27-31
50. Marsh GG, Markham CH: Does levodopa alter depression and psychopathology in Parkinsonism patients? J Neurol Neurosurg Psychiatry 1973; 36:925-935
51. Robins AH: Depression in patients with Parkinsonism. Br J Psychiatry 1976; 128:141-145
52. Brown GL, Wilson WP: Parkinsonism and depression. South Med J 1972; 65:540-545
53. Starkstein SE, Robinson RG: Dementia of depression in Parkinson's disease and stroke. J Nerv Ment Dis 1991; 179:593-601
54. Mayeux R, Stern Y, Cote L, et al: Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34:642-646
55. Mayeux R, Stern Y, Sano M, et al: The relationship of serotonin to depression in Parkinson's disease. Mov Disord 1988; 3:237-244
56. 3H)-paroxetine binding with the 5HT transporter in brain and platelets: relevance to studies in depression. J Receptor Res 1987; 7:499-521
57. 3H)-paroxetine binding sites in putamen. Neurology 1986; 36:556-560
58. Mayberg HS, Starkstein SE, Sadzot B, et al: Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990; 28:57-64
59. Ring HA, Bench CJ, Trimble MR, et al: Depression in Parkinson's disease: a positron emission study. Br J Psychiatry 1994; 165:333-339
60. Marin RS: Differential diagnosis of apathy and related disorders of diminished motivation. Psychiatric Annals 1997; 27:30-33
61. Starkstein SE, Mayberg HS, Preziosi TJ, et al: Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4:134-139
62. Levy ML, Cummings JL, Fairbanks LA, et al: Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998; 10:314-319
63. Rogers D, Lees AJ, Smith E, et al: Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness: an experimental study. Brain 1987; 1987:761-776
64. Mayeux R, Stern Y, Sano M, et al: Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. Neurology 1987; 37:1130-1134
65. Madeley P, Biggins CA, Boyd JL, et al: Emotionalism in Parkinson's disease. Ir J Pychol Med 1992; 9:24-25
66. Levin BE, Llabre MM, Weiner WJ: Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory. J Neurol Neurosurg Psychiatry 1988; 51:1401-1404
67. Diller L, Ricklan M: Psychosocial factors in Parkinson's disease. J Am Geriatr Soc 1956; 4:1291-1300
68. Mendez MF, Nakawatase TV, Brown CV: Involuntary laughter and inappropriate hilarity. J Neuropsychiatry Clin Neurosci 1999; 11:253-258
69. Menza MA, Robertson-Hoffman DE, Bonapace AS: Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34:465-470
70. Richard IH, Schiffer RB, Kurlan R: Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8:383-392
71. Rubin AJ, Kurlan R, Miller C, et al: Atypical depression and Parkinson's disease (abstract). Ann Neurol 1986; 20:150
72. Stein MB, Heuser IJ, Juncos JL, et al: Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990; 147:217-220
73. Berrios GE, Campbell C, Politynska BE: Autonomic failure, depression and anxiety in Parkinson's disease. Br J Psychiatry 1995; 166:789-792
74. Iruela LM, Ibanez-Rojo V, Palanca I, et al: Anxiety disorders and Parkinson's disease. Am J Psychiatry 1992; 149:719-720
75. Cash R, Dennis T, L'Heureux R, et al: Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 1987; 37:42-46
76. Lauterbach EC: The locus ceruleus and anxiety disorders in demented and nondemented familial parkinsonism (letter). Am J Psychiatry 1993; 150:994
77. Lauterbach EC, Duvoisin RC: Anxiety disorders in familial parkinsonism (letter). Am J Psychiatry 1992; 148:274
78. Henderson R, Kurlan R, Kersun JM, et al: Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4:257-264
79. Seimers ER, Shekhar A, Quaid K, et al: Anxiety and motor performance in Parkinson's disease. Mov Disord 1993; 8:501-506
80. Wolters EC: Dopaminomimetic psychosis in Parkinson's disease patients. Neurology 1999; 52(suppl 3):S10-S13
81. Peyser CE, Naimark D, Zuniga R, et al: Psychoses in Parkinson's Disease. Semin Clin Neuropsychiatry 1998; 3:41-50
82. Aarsland D, Larsen JP, Cummings JL, et al: Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: a community-based study. Arch Neurol 1999; 56:595-601
83. Hutchinson M, Fazzini E: Cholinesterase inhibition in Parkinson's disease (letter). J Neurol Neurosurg Psychiatry 1996; 61:324-325
84. Lieberman A: Managing the neuropsychiatrie symptoms of Parkinson's disease. Neurology 1998; 50(suppl 6):S33-S38
85. Starkstein SE, Petracca G: Parkinson's disease, in Psychiatric Treatment of the Medically III. Edited by Robinson RG, Yates WR. New York, Marcel Dekker, 1999, pp 443-457
86. Poewe W, Luginger E: Depression in Parkinson's disease: impediments to recognition and treatment options. Neurology 1999; 52(suppl 3):S2-S6
87. Juncos JL: Management of psychotic aspects of Parkinson's Disease. J Clin Psychiatry 1999; 60:42-53
88. Klaassen T, Verhey FR, Sneijders GH, et al: Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995; 7:281-286
89. Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340:757-763
90. Suchowersky O, de Vries JD: Interaction of fluoxetine and selegeline. Can J Psychiatry 1990; 35:571-572
91. Andersen J, Aabro E, Gulmann N, et al: Antidepressant treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 1980; 62:210-219
92. Laitinen L: Desipramine in treatment of Parkinson's disease: a placebo-controlled study. Acta Neurol Scand 1969; 45:109-113
93. Goetz CG, Tanner CM, Klawans HL: Bupropion in Parkinson's disease. Neurology 1984; 34:1092-1094
94. McCance-Katz EF, Marek KL, Price LH: Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology 1992; 42:1813-1814
95. Hauser RA, Zesiewicz TA: Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997; 12:756-759
96. Jansen Steur E: Increase of Parkinson disability after fluoxetine medication. Neurology 1993; 43:211-213
97. Chouinard G, Sultan S: A case of Parkinson's disease exacerbated by fluoxetine. Human Psychopharmacology 1992; 7:63-66
98. Faber R, Trimble MR: Electroconvulsive therapy in Parkinson's disease and other movement disorders. Mov Disord 1991; 6:293-303
99. Fall PA, Ekman R, Granerus AK, et al: ECT in Parkinson's disease: changes in motor symptoms, monoamine metabolites, and neuropeptides. J Neural Transm Park Dis Dement Sect 1995; 10:129-140
100. Factor SA, Molho ES, Podskalny GD, et al: Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995; 65:115-138
101. Zoldan J, Friedberg G, Weizman A, et al: Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Adv Neurol 1996; 69:541-544
102. Ellring H, Seiler S, Perleth B, et al: Psychosocial aspects of Parkinson's disease. Neurology 1993; 43(suppl 6):S41-S44
103. MacMahon DG: Parkinson's disease nurse-specialists: an important role in disease management. Neurology 1999; 52(suppl 3)S21-S25